Research Article

Update on Phenobarbital for Alcohol Withdrawal Syndrome in Intensive Care

Rukma Parthvi* and Parker Agne

Published: 07/22/2019 | Volume 4 - Issue 1 | Pages: 036-039

Abstract

Alcohol abuse is a global health problem. Alcohol withdrawal syndrome (AWS) ranges from mild to severe symptoms that can lead to fatal delirium tremens requiring ICU admission and incurring high health care cost as high as $20,000 a month. The latest published reports suggest that phenobarbital is a promising therapeutic option for management of AWS as evidenced by less ICU admissions, length of stay in hospital, use of adjunctive agents, health care costs and attention from the nursing staff than that of patients treated with commonly used benzodiazepines such as lorazepam, diazepam, and chlordiazepoxide. Phenobarbital is beneficial for the treatment of AWS, both in the emergency and inpatient settings and both as monotherapy or in conjunction with benzodiazepines. It is safe for patients without severe hepatic impairment, has a better mechanism of action and longer half-life than benzodiazepines, and leads to less delirium and agitation. Powered randomized controlled trials with large populations are required, yet phenobarbital can be used to safely to treat AWS.

Read Full Article HTML DOI: 10.29328/journal.jcicm.1001023 Cite this Article

References

  1. GBD Alcohol Collaborators. Alcohol use and burden for 195 countries and territories, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 2018; 392: 1015-1020. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/30146330
  2. Wood E, Albarqouni L, Tkachuk S, Green CJ, Ahamad K, et al. Will this hospitalized patient develop severe alcohol withdrawal syndrome? The rational clinical examination systematic review. JAMA. 2018; 320: 825-833. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/30167704
  3. Schmidt KJ, Doshi MR, Holzhausen JM, et al. Treatment of severe alcohol withdrawal. Ann Pharmacother. 2016; 50: 389-401.
  4. McKeown NJ, West PL. What is the mortality and morbidity of alcohol withdrawal syndrome? Medscape. 2018.
  5. Rosenson J, Clements C, Simon B, Vieaux J, Graffman S, et al. Phenobarbital for acute alcohol withdrawal: a prospective randomized double-blind placebo-controlled study. J Emerg Med. 2013; 44: 592-598. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/22999778
  6. Substance Abuse and Mental Health Services Administration (SAMHSA). 2015.
  7. How Much Does Medical Drug and Alcohol Withdrawal Cost? 2019.
  8. Hughes D. Benzodiazepine-refractory alcohol withdrawal.  Clinical, Critical Care, Toxicology. 2016.
  9. Grant BF, Goldstein RB, Saha TD. Epidemiology of DSM-5 alcohol use disorder: results from the National Epidemiologic Survey on Alcohol and Related Conditions III. JAMA Psychiatry. 2015; 72: 757-766.
  10. Farkas J. Phenobarbital monotherapy for alcohol withdrawal: simplicity and power. PulmCrit. 2015.
  11. Jin L, Schlesinger F, Song Y, Dengler R, Krampfl K.  The interaction of the neuroprotective compounds riluzole and phenobarbital with AMPA-type glutamate receptors: a patch clamp study. Pharmacology. 2010; 85: 54-62. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/20051697
  12. Nejad S, Chuang K, Hirschberg R. The use of antiepileptic drugs in acute neuropsychiatric conditions: focus on traumatic brain injury, pain, and alcohol withdrawal. Int J Clin Med. 2014; 5: 724-736.
  13. Hendey GW, Dery RA, Barnes RL, Snowden B, Mentler P. A prospective, randomized, trial of phenobarbital versus benzodiazepines for acute alcohol withdrawal. Am J Emerg Med. 2011; 29: 382-385. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/20825805
  14. Tidwell WP, Thomas TL, Pouliot JD, Canonico AE, Webber AJ. Treatment of alcohol withdrawal syndrome: phenobarbital vs CIWA-Ar protocol. Am J Crit Care.  2018: 27: 454-460. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/30385536
  15. Faust JS, Westafer L. Alcohol withdrawal treatment: bring back phenobarbital?  2018.
  16. Phenobarbital dosing, indications, interactions, adverse effects. 2019.
  17. Phenobarbital oral solution. 2019.
  18. Mann RE, Smart RG, Govoni, R. The epidemiology of Alcoholic liver disease. Alcohol Research &Health. 2003; 27: 209-213.